ArticleInfectious agents and cancer2025
Human papillomavirus type 16 and 18 in urothelial bladder neoplasms: detection, quantification, and comparison with non-neoplastic samples.
Article in Infectious agents and cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundBladder cancer is a prevalent urothelial cancer, and recent studies have focused on the potential role of Human Papillomavirus (HPV) in its development. This study investigates the prevalence and viral load of HPV types 16 and 18 in bladder urothelial neoplasms and compares these findings with non-neoplastic samples.
methodsA retrospective cross-sectional study was conducted using tissue samples from patients with urothelial bladder carcinoma (UBC) and a non-neoplastic control group. DNA was extracted and analyzed using real-time PCR to detect and quantify HPV types 16 and 18.
resultsAlthough the prevalence of high-risk HPV types (16 and 18) was higher in bladder cancer patients compared to controls, the difference was not statistically significant. However, HPV-16 viral load was significantly higher in patients (P < 0.001), and HPV-18 viral load was also significantly elevated (P = 0.004). Both HPV-16 and HPV-18 viral loads were generally higher in bladder cancer patients compared to healthy individuals.
conclusionThis study demonstrated an increased prevalence of high-risk HPV types in bladder urothelial neoplasms, with elevated viral loads for HPV-16 and HPV-18 in the cancer group. While these differences were not statistically significant, the increased viral load suggests that HPV may play a role in bladder cancer progression, particularly in cases of persistent infection. These findings highlight the importance of strengthening HPV vaccination programs and further investigation into the long-term effects of HPV on bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.